secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001999480-25-000089
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q3 net loss $14.2M; cash $184.2M after $50M PIPE; ALTO-207 on track for Phase 3 by early 2027
--------------------------------------------------------------------------------

- Net loss $14.2M vs $16.8M in Q3 2024; R&D expense $10.5M, G&A $4.4M.
- Cash $184.2M as of Oct 31 (incl. $49.9M net PIPE proceeds), projected to fund operations into 2028.
- ALTO-207 Phase 2b TRD trial start 1H 2026; Phase 3 by early 2027 after successful FDA meeting.
- Topline data expected: ALTO-101 CIAS (1Q 2026), ALTO-300 MDD (mid-2026), ALTO-100 BPD (2H 2026).
- ALTO-101 granted FDA Fast Track Designation for CIAS; blinded PK analyses showed 100% positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/0001999480-25-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/alto-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001999480-25-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer